| Assessment Status | Assessment Process Complete |
| HTA ID | 20061 |
| Drug | Mogamulizumab |
| Brand | Poteligeo® |
| Indication | For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 21/12/2020 |
| Rapid review completed | 21/01/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mogamulizumab (Poteligeo®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/01/2021 |
| Pre-submission consultation with Applicant | 23/03/2021 |
| Full submission received from Applicant | 07/10/2021 |
| Preliminary review sent to Applicant | 22/02/2022 |
| NCPE assessment re-commenced | 23/03/2022 |
| Follow-up to preliminary review sent to Applicant | 07/04/2022 |
| NCPE assessment re-commenced | 19/04/2022 |
| Factual accuracy sent to applicant | 17/06/2022 |
| NCPE assessment re-commenced | 24/06/2022 |
| NCPE assessment completed | 09/08/2022 |
| NCPE assessment outcome | The NCPE recommends that mogamulizumab (Poteligeo®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
